Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

MLA

Jabbour, Elias J., et al. “Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE.” Cancer (0008543X), vol. 124, no. 8, Apr. 2018, pp. 1722–32. EBSCOhost, https://doi.org/10.1002/cncr.31249.

APA

Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gökbuget, N., O’Brien, S., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, E., Advani, A. S., Kantarjian, H. M., & O’Brien, S. (2018). Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer (0008543X), 124(8), 1722–1732. https://doi.org/10.1002/cncr.31249

Chicago

Jabbour, Elias J., Daniel J. DeAngelo, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Gökbuget, Susan O’Brien, et al. 2018. “Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE.” Cancer (0008543X) 124 (8): 1722–32. doi:10.1002/cncr.31249.